Fierce Biotech

Kite puts $1.64B on the line for Pregene’s in vivo CAR-Ts

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...
GEN

Kite Pharma, Cell Design Labs Partner on CAR T-Cell Immunotherapies

Kite Pharma and Cell Design Labs said today they will partner to develop next-generation, precision-controlled chimeric antigen receptor (CAR) T-cell immunotherapy candidates using Cell Design Labs’ ...
Business Wire

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

SANTA MONICA, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Kite Pharma, Inc. (NASDAQ: KITE) (“Kite”) and Cell Design Labs, Inc. today announced a research collaboration and license agreement to develop ...
GEN

Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR-T Footprint

Gilead Sciences and its Kite cell therapy subsidiary have agreed to acquire Cell Design Labs for up to approximately $567 million, in a deal designed to grow the buyers’ footprint in chimeric antigen ...